Who dies from prostate cancer?

Area of Science:

• Oncology
• Urology
• Cancer Research

Background:

• Prostate cancer (CaP) remains a leading cause of cancer death in men despite shifts in initial staging.
• The incidence of metastases at diagnosis has decreased significantly in Western countries over the past 30 years.
• Castration-resistant prostate cancer (CRPC) represents a critical stage in advanced disease management.

Purpose of the Study:

• To describe the natural history of patients dying from prostate cancer in the modern era.
• To analyze the characteristics of patients with metastatic CRPC who died from the disease.
• To evaluate the diagnostic staging and progression patterns in fatal prostate cancer cases.

Main Methods:

• Analysis of two monthly curated databases of patients with CRPC.
• Study of the outcomes of 190 men with metastatic CRPC treated between 2008 and 2011.
• Detailed examination of the characteristics of 113 patients who died from CaP, including metastatic status at diagnosis.

Main Results:

• Approximately 56% of patients who died from CaP had detectable metastases at diagnosis (bone, visceral, or lymph node).
• The median time to CRPC was 16 months, with a median overall survival (OS) of 5.2 years.
• Among patients diagnosed with localized CaP, 64% were classified as high-risk, with a median OS of 8.8 years.

Conclusions:

• Roughly half of prostate cancer deaths in the modern era occur in patients with metastases detected at initial diagnosis.
• The observed data partially deviates from the typical progression model from localized disease to metastasis.
• Further research and clinical trials are crucial for patients newly diagnosed with metastatic prostate cancer.